- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02327702
Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients
December 29, 2014 updated by: Asian-Pacific Alliance of Liver Disease, Beijing
This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant chronic hepatitis B patients.
Single group patients were enrolled to receive emtricitabine till 48 weeks after delivery.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Single group patients were enrolled to receive emtricitabine till 48 weeks after delivery, which include HBeAg positive and negative patients.
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jun Cheng, M.D.
- Phone Number: +86 10 84322116
- Email: jun.cheng.ditan@gmail.com
Study Contact Backup
- Name: Song Yang, M.D.
- Phone Number: +86 15011210692
- Email: sduyangsong@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- HBsAg positive for more than 6 months
- HBeAg positive patients: HBV DNA ≥ 5log10 copies/ml
- HBeAg postive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver biopsy Knodell HAI ≥ 4
- HBeAg negative patients: HBV DNA ≥ 4log10 copies/ml
- HBeAg postive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver biopsy Knodell HAI ≥ 4
- Nucleoside/nucleotide naive patients
- Diagnosed as ≥ 12 weeks pregnancy
Exclusion Criteria:
- Diagnosed HCC with AFP and ultrasound, CT or MRI
- Creatine >130μmol/L or Ccr < 70mL/min
- Hemoglobin <100g/L
- Coinfected with HAV,HEV,HCV,HDV or HIV
- ANA > 1:100
- Uncontrolled cardiovascluar diseases, kidney diseases,lung diseases, neurological diseases, digestive diseases,metabolic disorders, immune-compromised diseases or cancer
- Drug abuse or alcohal addiction
- Previous history of taking agents of lamivudine, adefovir, tenofovir entecavir or telbivudine
- Long-term use of immunosuppressor or immunomodulator 6 months before enrollment to this trial
- Underwent liver transplantation or liver transplantation in schedule
- Allergic to nucleoside or nucleotide analogues
- Family history of genetic defects disease
- Abnormal results in fatal defects screening
- HBsAg positive sperm provider pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chinese naive pregnant chronice hepatitis B
Chinese naive pregnant chronice hepatitis B were enrolled to take emtricitabine (200 mg one time per day) till 48 weeks after delivery.
|
emtricitabine were given to each patients at baseline till 48 weeks after delivery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
virological response rate
Time Frame: week 48 after delivery
|
HBV DNA < 500 copies/ml
|
week 48 after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HBV DNA decrease level
Time Frame: week 24 and 48 after delivery
|
HBV DNA decrease compared with baseline(log10 copies/ml)
|
week 24 and 48 after delivery
|
virological response rate
Time Frame: week 24 after delivery
|
HBV DNA < 500 copies/ml
|
week 24 after delivery
|
biochemical response
Time Frame: week 24 and 48 after delivery
|
ALT normalization
|
week 24 and 48 after delivery
|
HBeAg loss
Time Frame: week 24 and 48 after delivery
|
HBeAg loss in HBeAg positive group
|
week 24 and 48 after delivery
|
HBeAg seroconversion
Time Frame: week 24 and 48 after delivery
|
HBeAg seroconversion in HBeAg positive group
|
week 24 and 48 after delivery
|
HBeAg reversion
Time Frame: week 24 and 48 after delivery
|
HBeAg positive in Baseline HBeAg negativie group patients
|
week 24 and 48 after delivery
|
HBsAg loss
Time Frame: week 24 and 48 after delivery
|
HBsAg loss
|
week 24 and 48 after delivery
|
HBsAg seroconversion
Time Frame: week 24 and 48 after delivery
|
HBsAg loss and anti-HBs positive
|
week 24 and 48 after delivery
|
HBV genetic resistance to emtricitabine
Time Frame: week 24 and 48 after delivery
|
HBV genetic resistance to emtricitabine
|
week 24 and 48 after delivery
|
adverse event
Time Frame: week 24 and 48 after delivery
|
type and rate of adverse events;type and rate of severe adverse event;
|
week 24 and 48 after delivery
|
birth defect in newborns
Time Frame: 0 weeks, week24 and week48 after delivery
|
birth defect in newborns
|
0 weeks, week24 and week48 after delivery
|
HBsAg positive rate in newborns
Time Frame: 0 weeks, week24 and week48 after delivery
|
HBsAg positive rate in newborns
|
0 weeks, week24 and week48 after delivery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jun Cheng, M.D., Asian Pacific Alliance of Liver Diseases, Beijing
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F; Emtricitabine FTCB-301 Study Group. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006 Jan 9;166(1):49-56. doi: 10.1001/archinte.166.1.49.
- Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother. 2002 Jun;46(6):1734-40. doi: 10.1128/AAC.46.6.1734-1740.2002.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Anticipated)
July 1, 2015
Study Completion (Anticipated)
July 1, 2017
Study Registration Dates
First Submitted
December 23, 2014
First Submitted That Met QC Criteria
December 29, 2014
First Posted (Estimate)
December 30, 2014
Study Record Updates
Last Update Posted (Estimate)
December 30, 2014
Last Update Submitted That Met QC Criteria
December 29, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Emtricitabine
Other Study ID Numbers
- FTC-02-pregnant CHB patients
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
Clinical Trials on Emtricitabine
-
Eastern Virginia Medical SchoolGilead Sciences; United States Agency for International Development (USAID); FHI... and other collaboratorsActive, not recruitingAdherence, Medication | Acceptability of Health CareSouth Africa, Zimbabwe
-
Gilead SciencesCompletedHIV InfectionsUnited States
-
University Health Network, TorontoGilead Sciences; University of Modena and Reggio Emilia; San Raffaele University... and other collaboratorsCompleted
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
University of California, San DiegoGilead Sciences; University at BuffaloCompleted
-
Vancouver Infectious Diseases CentreUnknownDrug Use | Human Immunodeficiency Virus I InfectionCanada
-
Valley AIDS CouncilGilead SciencesNot yet recruitingHIV-1-infection
-
University of NebraskaGilead SciencesCompleted
-
Fenway Community HealthCompleted
-
University of California, San DiegoActive, not recruitingHiv | Hormone TherapyUnited States